Abstract
Alzheimers disease is a neurodegenerative disorder characterized by amyloid deposits and neurofibrillary tangles. Cholinergic dysfunction is also a main pathological feature of the disease. Nevertheless, the links between cholinergic dysfunction and neuropathological hallmarks of Alzheimers are still unknown. In the present study, we aimed to further investigate Tau aggregation in cholinergic systems, in a Tau transgenic mouse model. THY-Tau22 mice have recently been described as a novel model of Alzheimer – like Tau pathology without motor deficits. This strain presents an age-dependent development of Tau pathology leading to synaptic dysfunctions as well as learning and memory impairments. In the present work, we observed that Tau pathology differentially affects cerebral structures. Interestingly, early Tau pathology was observed in both hippocampus and basal forebrain. Moreover, some morphological as well as functional alterations of the septohippocampal pathway suggest a disconnection between these two key brain regions in Alzheimers disease. Finally, these data suggest that Tau pathology may participate in cholinergic degeneration.
Keywords: Acetylcholine, axonal transport, basal forebrain, neurofibrillary tangles, phosphorylation
Current Alzheimer Research
Title: Early Tau Pathology Involving the Septo-Hippocampal Pathway in a Tau Transgenic Model: Relevance to Alzheimers Disease
Volume: 6 Issue: 2
Author(s): Karim Belarbi, Katharina Schindowski, Sylvie Burnouf, Raphaelle Caillierez, Marie-Eve Grosjean, Dominique Demeyer, Malika Hamdane, Nicolas Sergeant, David Blum and Luc Buee
Affiliation:
Keywords: Acetylcholine, axonal transport, basal forebrain, neurofibrillary tangles, phosphorylation
Abstract: Alzheimers disease is a neurodegenerative disorder characterized by amyloid deposits and neurofibrillary tangles. Cholinergic dysfunction is also a main pathological feature of the disease. Nevertheless, the links between cholinergic dysfunction and neuropathological hallmarks of Alzheimers are still unknown. In the present study, we aimed to further investigate Tau aggregation in cholinergic systems, in a Tau transgenic mouse model. THY-Tau22 mice have recently been described as a novel model of Alzheimer – like Tau pathology without motor deficits. This strain presents an age-dependent development of Tau pathology leading to synaptic dysfunctions as well as learning and memory impairments. In the present work, we observed that Tau pathology differentially affects cerebral structures. Interestingly, early Tau pathology was observed in both hippocampus and basal forebrain. Moreover, some morphological as well as functional alterations of the septohippocampal pathway suggest a disconnection between these two key brain regions in Alzheimers disease. Finally, these data suggest that Tau pathology may participate in cholinergic degeneration.
Export Options
About this article
Cite this article as:
Belarbi Karim, Schindowski Katharina, Burnouf Sylvie, Caillierez Raphaelle, Grosjean Marie-Eve, Demeyer Dominique, Hamdane Malika, Sergeant Nicolas, Blum David and Buee Luc, Early Tau Pathology Involving the Septo-Hippocampal Pathway in a Tau Transgenic Model: Relevance to Alzheimers Disease, Current Alzheimer Research 2009; 6 (2) . https://dx.doi.org/10.2174/156720509787602843
DOI https://dx.doi.org/10.2174/156720509787602843 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Circular, Cyclic and Acyclic ψ(CH2O) Containing Peptide Inhibitors of SKI- 1/S1P: Synthesis, Kinetic and Biochemical Evaluations
Current Medicinal Chemistry A Review for Lithium: Pharmacokinetics, Drug Design, and Toxicity
CNS & Neurological Disorders - Drug Targets Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Natural Products, the Continuous Source of Therapeutic Molecules for Various Diseases: Literature Landscape Analysis
Current Molecular Pharmacology Role of Environmental Contaminants in the Etiology of Alzheimer’s Disease: A Review
Current Alzheimer Research Chaperonin GroEL: Structure and Reaction Cycle
Current Protein & Peptide Science The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia
Current Topics in Medicinal Chemistry Anti-inflammatory Effects of Dietary Antioxidants
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Patent Selections :
Recent Patents on CNS Drug Discovery (Discontinued) Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery
Current Pharmaceutical Design The Discovery and Development of Drug Combinations for the Treatment of Various Diseases from Patent Literature (1980-Present)
Current Topics in Medicinal Chemistry Locus (Coeruleus) Minoris Resistentiae in Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Novel Genetic and Peptide-Based Strategies Targeting the Bcl-2 Family, an Update
Recent Patents on DNA & Gene Sequences Impacting Neuronal and Vascular Cellular Signal Transduction through the Metabotropic Glutamate Receptor System
Medicinal Chemistry Reviews - Online (Discontinued) A Role for Calcineurin in Alzheimers Disease
Current Neuropharmacology Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets Alterations in Glucose Metabolism on Cognition: A Possible Link Between Diabetes and Dementia
Current Pharmaceutical Design